Literature DB >> 37232

Enhanced transformability with heterospecific deoxyribonucleic acid upon removal of nascent ribonucleic acid from the Streptococcus sanguis genome.

P A Deddish, A W Ravin.   

Abstract

Treatment of Streptococcus sanguis recipient cells with rifampin (RIF) at the time of deoxyribonucleic acid (DNA) addition was an effective means of reducing discrimination, that is, of causing an increase in the number of transformants induced by irreversibly bound heterospecific DNA without significantly changing the number induced by bound homospecific DNA. RIF was unable to reduce discrimination when the recipient cells were RIF resistant due to an altered ribonucleic acid (RNA) polymerase. When recipient cells were treated at the time of DNA addition with concentrations of streptolydigin (STG) as inhibitory of RNA synthesis as RIF, discrimination was not reduced. The kinetics of RNA synthesis inhibition with these inhibitors indicated that, as reported for other bacterial species, RIF inhibited the initiation of transcription by RNA polymerase, whereas STG inhibited the progression of RNA polymerase at any point. Pulse-labeling of RNA immediately before STG addition showed that, if cells were incubated under STG inhibition for 10 to 15 min, their nascent RNA was degraded. Genome-bound RNA polymerase was not released under these conditions. When recipient cells were incubated with STG until nascent RNA was degraded and then exposed to transforming DNA, STG was as effective as RIF in reducing discrimination. The presence of nascent RNA was thereby implicated in the transforming inefficiency of incompletely homologous DNA.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37232      PMCID: PMC218126          DOI: 10.1128/jb.138.3.949-956.1979

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  17 in total

1.  Genetic hybridization at the unlinked thy and str loci of Streptococcus.

Authors:  A W Ravin; T Chakrabarti
Journal:  Genetics       Date:  1975-10       Impact factor: 4.562

2.  Fate of heterospecific transforming DNA bound to Streptococcus sanguis.

Authors:  J L Raina; E Metzer; A W Ravin
Journal:  J Bacteriol       Date:  1978-03       Impact factor: 3.490

3.  Heterospecific transformation of Pneumococcus and Streptococcus. IV. Variations in hybrid DNA produced by recombination.

Authors:  G D Biswas; A W Ravin
Journal:  Mol Gen Genet       Date:  1971

4.  Fractionation of denatured pneumococcal DNA: evidence for resolution of complementary strands.

Authors:  M Roger; C O Beckmann; R D Hotchkiss
Journal:  J Mol Biol       Date:  1966-06       Impact factor: 5.469

5.  Uptake of homologous single-stranded fragments by superhelical DNA: a possible mechanism for initiation of genetic recombination.

Authors:  W K Holloman; R Wiegand; C Hoessli; C M Radding
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

6.  Single-stranded regions in Streptococcus pneumoniae chromosomal deoxyribonucleic acid and their relation to transformation.

Authors:  P A Deddish; A W Ravin
Journal:  J Bacteriol       Date:  1979-03       Impact factor: 3.490

7.  Recombination promoted by superhelical DNA and the recA gene of Escherichia coli.

Authors:  W K Holloman; C M Radding
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

8.  Relation of macromolecular synthesis in streptococci to efficiency of transformation by markers of homospecific and heterospecific origin.

Authors:  P A Deddish; A W Ravin
Journal:  J Bacteriol       Date:  1974-03       Impact factor: 3.490

9.  Fate of homospecific transforming DNA bound to Streptococcus sanguis.

Authors:  J L Raina; A W Ravin
Journal:  J Bacteriol       Date:  1978-03       Impact factor: 3.490

10.  Enhanced transformability with heterospecific deoxyribonucleic acid in a Streptococcus sanguis mutant impaired in ribonucleic acid polymerase activity.

Authors:  J L Raina; A W Ravin
Journal:  J Bacteriol       Date:  1976-07       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.